Notizie AIOM – anno XV n. 626

26 Aprile 2017

FDA Schedules ODAC Meeting for Neratinib in HER2+ Breast Cancer

April 17, 2017 - The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for May 24, 2017, to discuss a new drug application (NDA) for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, ...
Leggi tutto

26 Aprile 2017

FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers

April 18, 2017 - On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Atezolizumab was ...
Leggi tutto

26 Aprile 2017

FDA Grants CTL019 Breakthrough Designation for DLBCL

April 18, 2017 - The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after the failure of at least 2 prior therapies, according to Novartis, ...
Leggi tutto

26 Aprile 2017

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer

Two previous single-arm trials have drawn conflicting conclusions regarding the activity of pazopanib in urothelial cancers after failure of platinum-based chemotherapy. This randomized (1:1) open-label phase II trial compared the efficacy of pazopanib 800 mg orally with ...
Leggi tutto

26 Aprile 2017

21 aprile 2017 – Farmaci e terapie “al femminile”: AIFA alla 2^ Giornata della Salute della Donna

21 Aprile 2017

Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1

While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive disease or HPD) under these agents have been described, suggesting potentially deleterious effects of these drugs. ...
Leggi tutto

21 Aprile 2017

ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm

Crizotinib, a mesenchymal-epithelial transition/anaplastic lymphoma kinase/c-ros oncogene 1 (ROS1) inhibitor, has recently been approved by the US Food and Drug Administration for the treatment of patients with advanced ROS1-positive non–small-cell lung cancer (NSCLC). ...
Leggi tutto

21 Aprile 2017

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

Maintenance therapy improves outcomes in various tumour types, but cumulative toxic effects limit the choice of drugs. We investigated whether maintenance therapy with vinflunine would delay disease progression in patients with advanced urothelial carcinoma who had achieved ...
Leggi tutto

21 Aprile 2017

Development of Human Papillomavirus (HPV) Vaccines: A Review of Literature and Clinical Update

The casual relationship concerning Human papillomaviruses (HPV) and cervical cancer is already established. Therefore, such HPV-associated malignancies might be prevented by prophylactic HPV vaccines. From 2009, two prophylactic HPV L1 Virus-Like Particle vaccines namely, ...
Leggi tutto

21 Aprile 2017

New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer With Radiation Therapy

April 18, 2017 - The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the management of oropharyngeal cancer. The guideline, “Radiation therapy for oropharyngeal squamous cell carcinoma: An ASTRO Evidence-based Clinical Practice ...
Leggi tutto

LAVORIAMO CON

News

GIORNATA MONDIALE DEL MALATO REUMATICO: NEL 2025 OLTRE 1,18 MILIONI DI CERTIFICATI PER PATOLOGIE MUSCOLO-SCHELETRICHE

IN ITALIA 55MILA DONNE VIVONO CON UN TUMORE AL SENO METASTATICO. ‘SERVE UN PDTA NAZIONALE UNIFORME, INTEGRATO E CENTRATO SULLA PERSONA’

TUMORE SENO METASTATICO: SERVONO PERCORSI SPECIFICI IN TUTTE LE BREAST UNIT. EUROPA DONNA ITALIA: «GARANTIRE PERCORSI DEDICATI, CON STANDARD DI QUALITÀ OMOGENEI SU TUTTO IL TERRITORIO NAZIONALE».

TUMORE SENO METASTATICO TRIPLO NEGATIVO, IN ITALIA OLTRE 8.200. CASI AIGOM: “TUTTE LE PAZIENTI SIANO SOTTOPOSTE AL TEST DEL BRCA”

EPATOCARCINOMA AVANZATO: IL 17% DEI PAZIENTI È VIVO A 6 ANNI. IL REGIME IMMUNOTERAPICO “STRIDE” MIGLIORA LA SOPRAVVIVENZA

TUMORE DEL SENO: 7 DONNE SU 10 COLPITE ANCHE DA VAMPATE DI CALORE. ‘NUOVA TERAPIA ORALE PUO’ CONTRASTARLE E FAVORIRE ADERENZA ALLE CURE’

FENILCHETONURIA: ITALIA RILEVANTE IN EUROPA PER INCIDENZA. “SCREENING NEONATALE PREVIENE DANNI NEUROLOGICI, MA NECESSARIA CONTINUITÀ DI CURA”

Notizie AIOM – anno XV n. 626

FDA Schedules ODAC Meeting for Neratinib in HER2+ Breast Cancer

FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers

FDA Grants CTL019 Breakthrough Designation for DLBCL

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer

21 aprile 2017 – Farmaci e terapie “al femminile”: AIFA alla 2^ Giornata della Salute della Donna

Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1

ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

Development of Human Papillomavirus (HPV) Vaccines: A Review of Literature and Clinical Update

New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer With Radiation Therapy